Literature DB >> 31408612

APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling.

Yi Liu1, Qingluan Liu1, Shumin Chen2, Yijun Liu1, Yumei Huang1, Pan Chen3, Xiayu Li4, Ge Gao1, Keqian Xu1, Songqing Fan5, Zhaoyang Zeng4, Wei Xiong4, Ming Tan4,6, Guiyuan Li4, Wenling Zhang1.   

Abstract

The apelin receptor (APLNR) is a GPCR involved in many pathophysiological processes; however, the correlation between APLNR expression and nasopharyngeal carcinoma (NPC) has not been reported. In this study, we used cDNA microarray data to determine APLNR expression levels in NPC tissues. We found that APLNR expression was reduced in NPC tissues compared with noncancerous nasopharyngeal epithelial tissues. Subsequently, a large-scale sample of 1015 tissues was used to validate this discovery and explore the relationship between APLNR expression and prognosis of NPC. Expression levels of APLNR in NPC tissues were indeed down-regulated. Furthermore, positive expression of APLNR in NPC predicted a better prognosis (disease-free survival: P = 0.001; overall survival: P < 0.001). Moreover, ingenuity pathway analysis revealed that an indirect interaction existed between APLNR and retinoic acid (RA) in the cancer regulatory network. Consistently, after treatment with all-trans-RA (ATRA), we found that APLNR was significantly up-regulated in NPC cell lines (5-8F and HNE1), and proliferation of NPC cells was inhibited. Cell cycle arrest occurred in the G0/G1 phase. In contrast, knockdown of APLNR diminished ATRA-induced growth inhibition of NPC cells. In addition, we surprisingly found that APLNR also played an important role in migration and invasion of NPC. Wound-healing and Transwell assays revealed that APLNR overexpression led to reduced migratory and invasive properties in 2 NPC cell lines. Western blot results revealed that hallmarks of epithelial-mesenchymal transition (EMT) were altered as well, suggesting that APLNR was capable of inhibiting EMT in NPC cells. Our study further demonstrated that low expression of APLNR promoted EMT in NPC cells by activating the PI3K-protein kinase B-mammalian target of rapamycin signaling pathway. Taken together, our data suggest that APLNR could potentially predict prognosis for patients with NPC and inhibit proliferation, migration, invasion, and EMT in nasopharyngeal cancer cells.-Liu, Y., Liu, Q., Chen, S., Liu, Y., Huang, Y., Chen, P., Li, X., Gao, G., Xu, K., Fan, S., Zeng, Z., Xiong, W., Tan, M., Li, G., Zhang, W. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling.

Entities:  

Keywords:  all-trans-RA; metastasis; prognosis; proliferation

Mesh:

Substances:

Year:  2019        PMID: 31408612     DOI: 10.1096/fj.201802416RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

1.  miR-26a-5p suppresses nasopharyngeal carcinoma progression by inhibiting PTGS2 expression.

Authors:  Binlin Cai; Xiu Qu; Dan Kan; Yi Luo
Journal:  Cell Cycle       Date:  2022-01-25       Impact factor: 4.534

2.  Retinoic acid can improve autophagy through depression of the PI3K-Akt-mTOR signaling pathway via RARα to restore spermatogenesis in cryptorchid infertile rats.

Authors:  Chunlan Long; Yu Zhou; Lianju Shen; Yihang Yu; Dong Hu; Xing Liu; Tao Lin; Dawei He; Tao Xu; Deying Zhang; Jing Zhu; Guanghui Wei
Journal:  Genes Dis       Date:  2021-04-02

3.  LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma.

Authors:  Ting Tang; Liting Yang; Yujian Cao; Maonan Wang; Shanshan Zhang; Zhaojian Gong; Fang Xiong; Yi He; Yujuan Zhou; Qianjin Liao; Bo Xiang; Ming Zhou; Can Guo; Xiaoling Li; Yong Li; Wei Xiong; Guiyuan Li; Zhaoyang Zeng
Journal:  Mol Oncol       Date:  2020-06-13       Impact factor: 6.603

4.  SNCG promotes the progression and metastasis of high-grade serous ovarian cancer via targeting the PI3K/AKT signaling pathway.

Authors:  Jing Zhang; Xiao-Han Liu; Cong Li; Xiao-Xing Wu; Yan-Lin Chen; Wen-Wen Li; Xian Li; Fan Gong; Qin Tang; Dan Jiang
Journal:  J Exp Clin Cancer Res       Date:  2020-05-07

Review 5.  Polychemotherapy with Curcumin and Doxorubicin via Biological Nanoplatforms: Enhancing Antitumor Activity.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Farid Hashemi; Amirhossein Zabolian; Hossein Saleki; Morteza Bagherian; Negar Azami; Atefe Kazemzade Bejandi; Kiavash Hushmandi; Hui Li Ang; Pooyan Makvandi; Haroon Khan; Alan Prem Kumar
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

6.  Dysregulation of miR-138-5p/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML.

Authors:  Dong-Hu Yu; Chen Chen; Xiao-Ping Liu; Jie Yao; Sheng Li; Xiao-Lan Ruan
Journal:  Front Cell Dev Biol       Date:  2021-02-26

7.  Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells.

Authors:  Senmao Li; Jindong Sheng; Zhenhua Liu; Yu Fan; Cuijian Zhang; Tianjing Lv; Shuai Hu; Jie Jin; Wei Yu; Yi Song
Journal:  J Cell Mol Med       Date:  2021-01-28       Impact factor: 5.310

8.  YB1 associates with oncogenetic roles and poor prognosis in nasopharyngeal carcinoma.

Authors:  Yuting Zhan; Xianyong Chen; Hongmei Zheng; Jiadi Luo; Yang Yang; Yue Ning; Haihua Wang; Yuting Zhang; Ming Zhou; Weiyuan Wang; Songqing Fan
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

9.  Identification of the alpha linolenic acid metabolism-related signature associated with prognosis and the immune microenvironment in nasopharyngeal carcinoma.

Authors:  Zhijie Fang; Hua Huang; Liyu Wang; Zhiqiang Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-05       Impact factor: 6.055

10.  miR-137 Inhibition of the Invasion, Metastasis, and Epithelial-Mesenchymal Transition of Nasopharyngeal Cancer by Regulating KDM1A.

Authors:  Han-Qiang Lu; Run-Kun Wang; Hui-Rong Wang; Guang-Quan Zhou; Yan-Shu Zhang
Journal:  J Oncol       Date:  2021-12-17       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.